Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthias Villalobos

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
BMC Palliative Care|May 25, 2022
Factors related to implementation of an interprofessional communication concept in thoracic oncology: a mixed-methods studyKatja Krug, Jasmin Bossert, Sophia Möllinger, et al.
Patient Preference and Adherence|October 21, 2016
Individual difficulties and resources - a qualitative analysis in patients with advanced lung cancer and their relativesAnika Sparla, Sebastian Flach-Vorgang, Matthias Villalobos, et al.
Zeitschrift Fur Evidenz, Fortbildung Und Qualitat Im Gesundheitswesen|July 28, 2019
[HeiMeKOM (Heidelberg Milestones Communication): development of an interprofessional intervention for improvement of communication in patients with limited prognosis]Matthias Villalobos, Anja Siegle, Laura Hagelskamp, et al.
Trials|August 16, 2018
The Heidelberg Milestones Communication Approach (MCA) for patients with prognosis <12 months: protocol for a mixed-methods study including a randomized controlled trialAnja Siegle, Matthias Villalobos, Jasmin Bossert, et al.
The Oncologist|April 16, 2021
Effects of an Interprofessional Communication Approach on Support Needs, Quality of Life, and Mood of Patients with Advanced Lung Cancer: A Randomized TrialKatja Krug, Jasmin Bossert, Nicole Deis, et al.
Medical Oncology (Northwood, London, England)|June 16, 2018
ERCC1 assessment in upfront treatment with and without cisplatin-based chemotherapy in stage IIIB/IV non-squamous non-small cell lung cancerMatthias Villalobos, Piotr Czapiewski, Niels Reinmuth, et al.
Oncology Letters|June 13, 2019
Impact of EMT in stage IIIB/IV NSCLC treated with erlotinib and bevacizumab when compared with cisplatin, gemcitabine and bevacizumabMatthias Villalobos, Piotr Czapiewski, Niels Reinmuth, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 7, 2010
Epoetin alfa in patients with advanced-stage Hodgkin's lymphoma: results of the randomized placebo-controlled GHSG HD15EPO trialAndreas Engert, Andreas Josting, Heinz Haverkamp, et al.
The European Respiratory Journal|March 21, 2015
Erlotinib and bevacizumab versus cisplatin, gemcitabine and bevacizumab in unselected nonsquamous nonsmall cell lung cancerMichael Thomas, Jürgen Fischer, Stefan Andreas, et al.
Gesundheitswesen (Bundesverband Der Arzte Des Offentlichen Gesundheitsdienstes (Germany))|April 16, 2021
[Heidelberg Milestones Communication (HeiMeKOM) - Experiences, Best Practice Examples and Recommendations from the Final Symposium on January 30 and 31 in 2020]Matthias Villalobos, Nicole Deis, Simone Wesselmann, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
BMC Palliative Care|May 25, 2022
Factors related to implementation of an interprofessional communication concept in thoracic oncology: a mixed-methods studyKatja Krug, Jasmin Bossert, Sophia Möllinger, et al.
Patient Preference and Adherence|October 21, 2016
Individual difficulties and resources - a qualitative analysis in patients with advanced lung cancer and their relativesAnika Sparla, Sebastian Flach-Vorgang, Matthias Villalobos, et al.
Zeitschrift Fur Evidenz, Fortbildung Und Qualitat Im Gesundheitswesen|July 28, 2019
[HeiMeKOM (Heidelberg Milestones Communication): development of an interprofessional intervention for improvement of communication in patients with limited prognosis]Matthias Villalobos, Anja Siegle, Laura Hagelskamp, et al.
Trials|August 16, 2018
The Heidelberg Milestones Communication Approach (MCA) for patients with prognosis <12 months: protocol for a mixed-methods study including a randomized controlled trialAnja Siegle, Matthias Villalobos, Jasmin Bossert, et al.
The Oncologist|April 16, 2021
Effects of an Interprofessional Communication Approach on Support Needs, Quality of Life, and Mood of Patients with Advanced Lung Cancer: A Randomized TrialKatja Krug, Jasmin Bossert, Nicole Deis, et al.
Medical Oncology (Northwood, London, England)|June 16, 2018
ERCC1 assessment in upfront treatment with and without cisplatin-based chemotherapy in stage IIIB/IV non-squamous non-small cell lung cancerMatthias Villalobos, Piotr Czapiewski, Niels Reinmuth, et al.
Oncology Letters|June 13, 2019
Impact of EMT in stage IIIB/IV NSCLC treated with erlotinib and bevacizumab when compared with cisplatin, gemcitabine and bevacizumabMatthias Villalobos, Piotr Czapiewski, Niels Reinmuth, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 7, 2010
Epoetin alfa in patients with advanced-stage Hodgkin's lymphoma: results of the randomized placebo-controlled GHSG HD15EPO trialAndreas Engert, Andreas Josting, Heinz Haverkamp, et al.
The European Respiratory Journal|March 21, 2015
Erlotinib and bevacizumab versus cisplatin, gemcitabine and bevacizumab in unselected nonsquamous nonsmall cell lung cancerMichael Thomas, Jürgen Fischer, Stefan Andreas, et al.
Gesundheitswesen (Bundesverband Der Arzte Des Offentlichen Gesundheitsdienstes (Germany))|April 16, 2021
[Heidelberg Milestones Communication (HeiMeKOM) - Experiences, Best Practice Examples and Recommendations from the Final Symposium on January 30 and 31 in 2020]Matthias Villalobos, Nicole Deis, Simone Wesselmann, et al.
Pageof 3